Drug Profile
RX 0201
Alternative Names: Archexin; Archexin-Nano; F-LCAN-RX-0201; RX 0201-N; RX-0201; RX-0201 nanoliposomal; RX-0201-Nano; WGI-0201Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Rexahn Pharmaceuticals
- Developer Rexahn Pharmaceuticals; The WhiteOak Group
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer; Renal cell carcinoma
- Phase I Liver cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical studies in Solid tumours were presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 15 Mar 2022 Clinical development is ongoing USA (The WhiteOak Group pipeline, March 2022)
- 15 Mar 2022 Phase-I clinical trials in Liver cancer in USA (IV) (The WhiteOak Group pipeline, March 2022)